Fig. 3From: A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medicationsExpiry Dates of Patented Cancer Drugs on the 19th, 20th, and 21st Editions of the WHO EML (2015–2019)Back to article page